Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type II collagen is a fibrillar protein that forms the primary structural component of hyaline cartilage, including articular cartilage at joint surfaces. It is essential for providing tensile strength and maintaining the integrity of cartilage tissue. In humans, type II collagen constitutes about 50% of all protein in cartilage and 85–90% of the total collagen content in articular cartilage. Oral administration of native or undenatured type II collagen can induce oral tolerance—a process where immune reactivity against specific antigens decreases—potentially reducing autoimmune attacks on joint tissue.
Oral administration of native or undenatured type II collagen can induce oral tolerance—a process where immune reactivity against specific antigens decreases—potentially reducing autoimmune attacks on joint tissue. This mechanism involves induction of regulatory T cells (Tregs) that secrete anti-inflammatory cytokines such as IL-10 to inhibit inflammation in joints. Hydrolyzed forms may act differently by supplying amino acids for tissue repair rather than modulating immunity directly.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Type II Collagen (CII).